The search for effective treatments for Pompe disease, a rare and debilitating genetic disorder, has received a boost with the enrollment of the first patients in Shionogi’s global Phase II Esprit trial. The study is evaluating S-606001, an investigational oral substrate reduction therapy (SRT), in adults living with late-onset Pompe disease (LOPD). This marks a significant step forward in addressing the unmet needs of patients with this challenging condition.
Pompe disease, also known as glycogen storage disease type II, stems from a deficiency in the enzyme acid alpha-glucosidase (GAA). This deficiency leads to the accumulation of glycogen, a form of sugar, in various tissues throughout the body, particularly muscle tissue. The buildup disrupts normal cellular function, causing progressive muscle weakness and a range of other symptoms. While both children and adults can be affected, LOPD typically presents later in life and progresses more slowly than the infantile-onset form of the disease. According to the National Organization for Rare Disorders (NORD), the prevalence of Pompe disease is estimated to be 1 in 50,000 live births. https://rarediseases.org/rare-diseases/pompe-disease/
The Esprit trial, a randomized, multi-center, double-blind, placebo-controlled study, will enroll participants across the European Union, the United Kingdom, and the United States. The 52-week trial aims to assess the pharmacodynamics – how the drug affects the body – as well as preliminary efficacy and safety of S-606001 when used in conjunction with standard enzyme replacement therapy (ERT). ERT is currently the mainstay of treatment for Pompe disease, working by providing patients with a functional version of the missing GAA enzyme. However, the benefits of ERT can diminish over time, highlighting the need for complementary therapies.
How S-606001 Works: Targeting Glycogen Metabolism
S-606001 represents a novel approach to treating Pompe disease. Unlike ERT, which focuses on increasing the breakdown of glycogen, S-606001 is a substrate reduction therapy. This means it aims to reduce the *production* of glycogen, thereby lessening the burden on the deficient GAA enzyme. Specifically, the drug is designed to block glycogen synthase (GYS1), the enzyme responsible for creating glycogen. By inhibiting GYS1, S-606001 is thought to reduce glycogen accumulation within muscle lysosomes, the cellular compartments where glycogen is stored. Research published in 2025 in Nature detailed the mechanism by which GYS1 reorganizes into nuclear condensates and its interaction with the transcription factor NONO/p54nrb, further illuminating the potential of targeting this enzyme. https://www.nature.com/articles/s41418-025-01509-4
This dual-pronged approach – combining ERT to enhance glycogen breakdown with SRT to limit glycogen production – could offer a more comprehensive strategy for managing Pompe disease. Researchers believe that by addressing both sides of the metabolic imbalance, they can potentially slow disease progression and improve outcomes for patients.
Shionogi’s Commitment and Regulatory Progress
Shionogi’s commitment to developing new therapies for Pompe disease was solidified in 2024 with the acquisition of exclusive global rights to S-606001 from Maze Therapeutics. The company has since been working diligently to advance the drug through clinical development and secure regulatory designations that could expedite its path to market. In 2025, S-606001 received both the Rare Pediatric Disease designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA). These designations provide incentives for companies developing treatments for rare diseases, including tax credits, fee waivers, and potential market exclusivity. https://www.clinicaltrialsarena.com/news/shionogi-pompe-disease-drug-s-606001-phase-2-trial/
Juan Carlos Gomez, Shionogi’s chief medical officer, emphasized the urgent need for new treatment options. “Currently, ERTs are the standard of care for LOPD, but their efficacy can wane over time, leading to continued decline in skeletal muscle function,” he stated. “There is a significant unmet need for new treatment approaches that can be complementary to existing treatments to further slow disease progression.”
Beyond Pompe Disease: Shionogi’s RSV Antiviral Success
Shionogi’s research pipeline extends beyond Pompe disease. In January 2025, the company announced positive results from a Phase II study of its oral antiviral for respiratory syncytial virus (RSV). The study, conducted as a human challenge trial, demonstrated that the antiviral significantly reduced viral load in participants, with some experiencing an 88.94% reduction. https://www.clinicaltrialsarena.com/news/shionogi-rsv-antiviral-reduces-viral-load-in-phase-ii-human-challenge-trial/ This success underscores Shionogi’s growing expertise in antiviral drug development and its commitment to addressing significant public health challenges.
What’s Next for S-606001 and Pompe Disease Patients?
The initiation of the Esprit trial represents a crucial milestone in the development of S-606001. Researchers will be closely monitoring participants throughout the 52-week study to assess the drug’s impact on glycogen levels, muscle function, and overall quality of life. While the results of the Phase II trial are still pending, the potential of S-606001 to offer a new therapeutic avenue for Pompe disease patients is generating considerable excitement within the medical community.
The ongoing research into glycogen metabolism and the development of innovative therapies like S-606001 offer hope for individuals and families affected by Pompe disease. As the Esprit trial progresses, the world will be watching closely for updates on this promising new treatment.
The next major checkpoint will be the completion of the Phase II Esprit trial and the subsequent analysis of the data, anticipated in late 2026 or early 2027. We encourage readers to share their thoughts and experiences with Pompe disease in the comments below. Please consult with your healthcare provider for the most up-to-date information and guidance on managing this complex condition.
Worth a look